Version 1 of 39 (2007-07-13 to 2008-02-12) was submitted prior to the Lobbying Act coming into force on July 2, 2008. Due to different information requirements at that time, the registration is presented in the following format.
Corporation: |
Novartis Pharmaceuticals Canada Inc.
385 Bouchard Blvd. Dorval, QC H9S 1A9 Canada |
Telephone number: | 514-633-7880 Ext.: 3395 |
Fax number: | 514-631-0307 |
Responsible officer name and position during the period of this registration: | David Meek, President |
Description of activities: | Marketing & distribution of pharmaceuticals products. |
Parent: | The corporation is not a subsidiary of any other parent corporations. |
Coalition | The corporation is not a member of a coalition. |
Subsidiary: | The corporation does not have any subsidiaries that could be affected by the outcome of the undertaking. |
Other direct interests | The corporation's activities are not controlled or directed by another individual, organization or corporation with a direct interest in the outcome of this undertaking. |
Was the corporation funded in whole or in part by any domestic or foreign government institution in the last completed financial year? | No |
Name: | Alain Boisvert |
Position title: | VP, Health Policy & Market Access |
Public offices held: | No |
Name: | Shona Kinley |
Position title: | Director, Health Policy - Atlantic Canada & Federal |
Public offices held: | Yes |
Name: | Patricia Manzi |
Position title: | National Director, Health Policy |
Public offices held: | No |
Federal departments or organizations which have been or will be communicated with during the course of the undertaking: | Atlantic Canada Opportunities Agency (ACOA), Fisheries and Oceans Canada (DFO), Foreign Affairs and International Trade Canada (DFAITC), Health Canada (HC), National Defence (DND), Veterans Affairs Canada (VAC) | ||||||||
Communication techniques that have been used or are expected to be used in the course of the undertaking:
|
Informal communications, Meetings, Presentations, Telephone calls, Written communications, whether in hard copy or electronic format | ||||||||
Subject Matter: Areas of Concern: | Health, Industry, Intellectual Property, Science and Technology | ||||||||
Subject Matter: Retrospective: | Intellectual Property re: Data protection | ||||||||
Subject Matter: Prospective: | Develop business relationships and discuss the innovation agenda and other Novartis federal isses as they arise. | ||||||||
Details Regarding the Identified Subject Matter
|